Related Experiment Video
Updated: Nov 19, 2025

Optocardiography and Electrophysiology Studies of Ex Vivo Langendorff-perfused Hearts
Published on: November 7, 2019
[Cardiology]
Nadia Kilani1, Christelle Haddad1, Henri Lu1
1Service de cardiologie, CHUV, Université de Lausanne, 1011 Lausanne.
Insights
New European Society of Cardiology guidelines highlight SGLT2 inhibitors for heart failure and stress MRI for coronary artery disease screening. Transcatheter aortic valve replacement may allow anti-platelet monotherapy, and certain blood pressure drugs don't increase COVID-19 risk.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Imaging
Background:
- The European Society of Cardiology released updated guidelines in 2020.
- Key areas include non-ST-segment elevation acute coronary syndromes, atrial fibrillation, and adult congenital heart disease.
- Advances in interventional cardiology, heart failure treatment, and cardiac imaging were noted.
Purpose of the Study:
- To summarize significant findings and guideline updates from 2020 in cardiology.
- To highlight advancements in transcatheter aortic valve replacement (TAVI) and heart failure pharmacotherapy.
- To review the role of cardiac imaging and the impact of specific medications on COVID-19 risk.
Main Methods:
- Review of 2020 European Society of Cardiology guidelines.
- Analysis of key clinical trials like POPular TAVI and EMPEROR-Reduced.
- Evaluation of the utility of stress MRI and the safety of renin-angiotensin-aldosterone inhibitors concerning COVID-19.
Main Results:
- POPular TAVI trial suggests potential for anti-platelet monotherapy post-transcutaneous aortic valve replacement.
- EMPEROR-Reduced trial reinforces the efficacy of SGLT2 inhibitors in heart failure with reduced ejection fraction.
- Stress MRI is established as a first-line, cost-effective screening tool for coronary artery disease.
- Renin-angiotensin-aldosterone inhibitors were not associated with an increased risk of COVID-19 infection.
Conclusions:
- 2020 cardiology guidelines offer significant updates for clinical practice.
- New therapeutic strategies and diagnostic tools are improving patient outcomes.
- Current evidence supports the safety of certain cardiovascular medications in the context of COVID-19.
Abstract:
In 2020, new guidelines have been published by the European Society of Cardiology including those on non-ST-segment elevation acute coronary syndromes, atrial fibrillation and adult congenital heart disease. Regarding interventional cardiology, POPular TAVI opens the possibility of anti-platelet monotherapy after transcutaneous aortic valve replacement. EMPEROR-Reduced confirms the importance of SGLT2 inhibitors in the treatment of heart failure with reduced ejection fraction. Within the field of imaging, stress MRI has now become the first-line technique for the screening of coronary artery disease, demonstrating an excellent cost-benefit ratio. Finally, renin-angiotensin-aldosterone inhibitors do not appear to increase the risk of an infection by COVID-19.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy V: Interprofessional Care
Introduction Cardiac Emergencies
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiovascular Drugs: Classification based on Therapeutic Indications
Imaging Studies for Cardiovascular System V: CT

